# A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

Study · id `cardio:ct-nct01518998` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01518998](<https://clinicaltrials.gov/study/NCT01518998>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01518998

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.

## Technical summary

Registry record NCT01518998. Randomized; double masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2013-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 420 participants (enrolled count; ClinicalTrials.gov record NCT01518998, source copy `cardio:ctgov-nct01518998-2016-07-01`, retrieved 2026-10-26)
- Start date: 2011-08 (registry gives no type) (ClinicalTrials.gov record NCT01518998, source copy `cardio:ctgov-nct01518998-2016-07-01`, retrieved 2026-10-26)
- Primary completion: 2013-10 (actual) (ClinicalTrials.gov record NCT01518998, source copy `cardio:ctgov-nct01518998-2016-07-01`, retrieved 2026-10-26)
- Completion: 2013-11 (actual) (ClinicalTrials.gov record NCT01518998, source copy `cardio:ctgov-nct01518998-2016-07-01`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01518998, source copy `cardio:ctgov-nct01518998-2016-07-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01518998-2016-07-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension
- Condition: Hypertension
- Intervention (Drug): Fimasartan , Amlodipine, Placebo
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY
- Collaborator: Gachon University Gil Medical Center
- Collaborator class: OTHER
- Collaborator: The Catholic University of Korea
- Collaborator class: OTHER
- Collaborator: Kyungpook National University Hospital
- Collaborator class: OTHER
- Collaborator: Daegu Catholic University Medical Center
- Collaborator class: OTHER
- Collaborator: Wonkwang University Hospital
- Collaborator class: OTHER
- Collaborator: Wonju Severance Christian Hospital
- Collaborator class: OTHER
- Collaborator: Korea University Guro Hospital
- Collaborator class: OTHER
- Collaborator: DongGuk University
- Collaborator class: OTHER
- Collaborator: Yeungnam University Hospital
- Collaborator class: OTHER
- Collaborator: Chonnam National University Hospital
- Collaborator class: OTHER
- Collaborator: Cheil General Hospital and Women's Healthcare Center
- Collaborator class: OTHER
- Collaborator: Chungnam National University
- Collaborator class: OTHER
- Collaborator: Asan Medical Center
- Collaborator class: OTHER
- Collaborator: Seoul National University Bundang Hospital
- Collaborator class: OTHER
- Collaborator: Inha University Hospital
- Collaborator class: OTHER
- Collaborator: Seoul National University Hospital
- Collaborator class: OTHER
- Collaborator: Inje University
- Collaborator class: OTHER
- Collaborator: Samsung Medical Center
- Collaborator class: OTHER
- Collaborator: Pusan National University Yangsan Hospital
- Collaborator class: OTHER
- Collaborator: Soon Chun Hyang University
- Collaborator class: OTHER
- Collaborator: Catholic University of Korea Saint Paul's Hospital
- Collaborator class: OTHER
- Collaborator: Hallym University Kangnam Sacred Heart Hospital
- Collaborator class: OTHER
- Collaborator: Jeju National University Hospital
- Collaborator class: OTHER
- Collaborator: Hanyang University Seoul Hospital
- Collaborator class: OTHER
- Collaborator: Kangbuk Samsung Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension (`cardio:pubmed-25850881`)

Courtesy of the U.S. National Library of Medicine.

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 21 registry organizations

## Provenance

Content hash: 32a940973b284771ab62bc600e92dadd9db04004038161605d69ba983e280db7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
